TWST · NASDAQ · STOCK
Twist Bioscience (TWST) Stock Analysis
$159.82
52W $23.30 – $219.71
59/100
$9.95B
-72.0
2.19
Is TWST Bullish or Bearish?
Bullish.
Innellis AI committee rates Twist Bioscience Corporation (TWST) Buy with a composite score of 59/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.65 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.35 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.20 across 19 articles, 14d) — News
Bear Case
- ROE of only -29.9% -- cheap may mean cheap for a reason — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 46.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 35%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -29.9% -- cheap may mean cheap for a reason
Growth Analyst
neutral
57
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 46.1% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 19 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 59.4 to 59.4.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
43.0
Neutral
MACD Histogram
-4.263
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.39
Inside Bands
Price vs Moving Averages
EMA 9
$169.13
Below
EMA 21
$164.90
Below
EMA 50
$145.61
Above
EMA 200
$93.95
Above
Fundamental Analysis
Valuation
65
Growth
31
Profitability
20
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-72.0×
P/B Ratio
22.37×
PEG Ratio
1.10
Dividend Yield
0.00%
52W High
$219.71
52W Low
$23.30
Quality & Growth
ROE
-1642.2%
ROA
-1210.1%
Gross Margin
5196.5%
Operating Margin
-3190.7%
Revenue Growth YoY
—
Debt / Equity
0.21
AI Fundamental Assessment
P/E ratio of -72.0 (inexpensive relative to a 15-40x range); Price-to-book of 22.4x; PEG ratio of 1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -16.4%; Return on assets of -12.1%; Net margin of -31.7%; Gross margin of 52.0%; Current ratio of 2.67 (healthy short-term liquidity); Debt-to-equity of 0.21; Free cash flow per share is negative (-1.49); Most recent quarter missed estimates by 11.2%; 4 consecutive earnings misses; EPS growth accelerating (-18.0% -> +5.1% QoQ); Analyst estimates falling over recent quarters
Get the Full TWST Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →